trending Market Intelligence /marketintelligence/en/news-insights/trending/kudsltqorb6dpjvvg1f7pw2 content esgSubNav
In This List

Endocyte plans $175M common stock offering to fund prostate cancer drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Endocyte plans $175M common stock offering to fund prostate cancer drug

Endocyte Inc. is planning a public offering to sell $175 million of its common shares.

The West Lafayette, Ind.-based company intends to use the net proceeds to fund the clinical development of its pipeline products, to prepare for the launch of prostate cancer drug Lu-PSMA-617, if approved, as well as for working capital and general corporate purposes.

Endocyte expects to grant the underwriters an option to buy up to an additional $26.3 million of common shares.

Jefferies LLC, Wells Fargo Securities LLC and RBC Capital Markets LLC are acting as joint book-running managers for the proposed offering.

Endocyte is a biopharmaceutical company that develops targeted therapies for treating cancer and inflammatory diseases.